Skip to main content

SYSTEMATIC REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1416068
This article is part of the Research Topic Community Series in Novel Biomarkers in Tumor Immunity and Immunotherapy: Volume II View all 7 articles

Prognostic and clinicopathological value of systemic immune-inflammation index in patients with osteosarcoma: a meta-analysis

Provisionally accepted
Zhong Wu Zhong Wu 1Zongxin Zhang Zongxin Zhang 2Ziwei Jiang Ziwei Jiang 3*
  • 1 Nanxun District Hospital of Traditional Chinese Medicine, Huzhou, China
  • 2 Huzhou Central Hospital, Huzhou, China
  • 3 People's Hospital of Anji, Huzhou, China

The final, formatted version of the article will be published soon.

    Background: The efficiency of systemic immune-inflammation index (SII) in predicting prognosis of osteosarcoma (OSA) patients has been extensively analyzed, but no consistent findings are obtained. Therefore, this meta-analysis focused on identifying the precise prognostic value of SII for OSA. Methods: We comprehensively searched electronic databases of PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure (CNKI) from inception to 24 February, 2024. Meanwhile, the efficiency of SII in predicting prognosis of OSA was evaluated by calculating pooled hazard ratios (HRs) as well as 95% confidence intervals (CIs). Additionally, the correlation of SII with the OSA clinicopathological characteristics was analyzed based on pooled odds ratios (ORs) and 95%CIs. Results: Six studies with 1015 cases were enrolled into this work. According to the combined data, the higher SII was markedly related to poor overall survival (OS) (HR=2.01, 95%CI=1.30-3.09, p=0.002) and Enneking stage III (OR=2.21, 95%CI=1.11-4.39, p=0.024) of patients with OSA. Nonetheless, SII was not significantly related to gender, age, pathological fracture, tumor size, tumor location, tumor differentiation, and metastasis in patients with OSA. Conclusions: In summary, the higher SII is markedly related to poor OS and advanced Enneking stage in OSA patients.

    Keywords: systemic immune-inflammation index, Meta-analysis, Osteosarcoma, Evidence-Based Medicine, prognosis

    Received: 11 Apr 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Wu, Zhang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ziwei Jiang, People's Hospital of Anji, Huzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.